toovorti.blogg.se - Story reader video plus replacement controller

#STORY READER VIDEO PLUS REPLACEMENT CONTROLLER PDF#
#STORY READER VIDEO PLUS REPLACEMENT CONTROLLER REGISTRATION#
#STORY READER VIDEO PLUS REPLACEMENT CONTROLLER FREE#

Original articles reporting randomized trials must follow CONSORT recommendations, meta-analyses and guidelines PRISMA recommendations, observational studies STROBE recommendations, and studies of diagnostic accuracy STARD guidelines. Additional figures and tables can be published as Supplementary data.

Figure and Tables, maximum 8 items in total.

When required, further information on methodology can be provided in the Supplementary data. The methods section (maximum 500 words) should include the most important methods that allow readers to understand the article content. The Methods and Results sections can be divided with specific subtitles.

Main text (Introduction, Methods, Results, Discussion) maximum 4,000 words.

In this case, explain their meaning when they are first used. Use abbreviations only for terms that occur at least twice.

#STORY READER VIDEO PLUS REPLACEMENT CONTROLLER REGISTRATION#

Articles reporting clinical trials should provide the trial registration number at the end of the abstract. Abstract (unstructured), maximum 250 words.The manuscript are to be divided into sections under the following subheadings: Abstract, Introduction, Methods, Results, Discussion, and References. There is no limit to the number of authors, but this must be commensurate with the complexity of the study. Potential conflicts of interest of single authors are not considered an obstacle for publication (all authors are required to disclose competing interests during the online submission process).

Haematologica does not even consider for publication papers not reporting primary data whose preparation has been promoted, sponsored or supported in any way by a company whose product is discussed in the paper.

#STORY READER VIDEO PLUS REPLACEMENT CONTROLLER PDF#

A PDF of the preprint must be included in the submission as a supplementary file.

The existence of a preprint must be explicitly stated in the submission form and in the cover letter for the submission.

Preprints, as well as any related public comments, will be considered in the evaluation of the manuscript submitted to Haematologica.

The preprint must not be modified while the manuscript is under evaluation and cannot be updated if the manuscript is accepted for publication in Haematologica.

Once published in Haematologica, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the Haematologica website.

Preprint is allowed under these conditions: Meeting abstracts and manuscripts released as a preprint before or during submission are the only exception. Haematologica does not publish the results of studies that have already been published, even partially, or are going to be published in any form.

Papers that focus primarily on disorders of vessels, atherosclerosis included, are outside the scope of Haematologica and will not be considered for publication. Haematologica considers for publication manuscripts on physiology and pathophysiology of hematopoiesis and blood cells as well as clinical studies on disorders that hematology departments take care of.

#STORY READER VIDEO PLUS REPLACEMENT CONTROLLER FREE#

A high quality of articles, immediate free access to everything published and the lowest possible cost for authors are the principles that inspire Haematologica management. Haematologica is the main tool through which the Ferrata-Storti Foundation, a non-profit organization, promotes the dissemination of new knowledge in the field of hematology.